CA-based Deep Apple Therapeutics Secures $52M in Series A Round Funding. Apple Tree Partners headed the round. The funds will be used by the business to expand both its operations and growth initiatives.
Under the leadership of founding CEO Spiros Liras, Ph.D., Deep Apple uses a discovery engine that combines molecular docking screens of ultra-large libraries, ensemble cryo-EM, and deep learning to go from target identification to lead optimisation in less than a year in order to pursue biological target signalling that is not available to traditional discovery approaches.
Read also – Canada-based Friendlier Secures $5M in Funding
Its discovery engine is especially well-suited for rapid hit-finding against integral membrane proteins and is widely relevant across disease domains.
The business is presently developing a number of projects centred on GPCR modulators, a tested target class having uses in immunology, endocrine illnesses, inflammation, and metabolic disorders.
Read also – FL-based SellersFi Secures Funding of Undisclosed Amount
The drug discovery engine of Deep Apple is based on the cutting-edge knowledge and technologies of its academic co-founders, John Irwin, Ph.D., of UCSF, Brian Shoichet, Ph.D., of the University of California San Francisco (UCSF), and Georgios Skiniotis, Ph.D., of Stanford University, a global leader in cryo-EM and GPCR structural biology.
The author of the popular ZINC free virtual library, which has over 10 billion synthesizable chemicals, is a computational library authority.
Read also – PA-based PennSpring Capital Acquired Zirtual
About Deep Apple Therapeutics
Discovering new small compounds for high-value targets at an unparalleled pace is the goal of Deep Apple Therapeutics. Deep Apple leverages a combination of deep learning, docking multi-billion molecule libraries produced by the company’s proprietary Orchard.aiTM technology, and ensemble cryo-EM to investigate receptor conformations.
Read also – MO-based Simplifield E-Solutions Secures an Investment from HCAP
